Despite low Merlin tumour expression being a negative prognostic factor in patients with mesothelioma, our results suggest that mesothelioma patients with absent or low Merlin expression have a longer duration of treatment than Merlin-positive patients when administered GSK2256098.18 These current findings confirm the prior monotherapy findings of GSK2256098. Here, NF2 is linked to mesothelioma.